Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Orestes Antonio Pavia
Observed names:
O Pavia,
O. A. Pavia,
O. Pavia,
Orestes A. Pavia,
Orestes Pavia,
Orestes Pavía
show all 6
Institution:
Auxilio Mutuo Hospital
Observed institutions:
Moffitt Cancer Center,
Auxilio Mutuo Hospital
OpenAlex ID:
A5018716591
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
2006
·
F. Cabanillas
, I. Liboy
, et al.
·
Annals of Oncology
·
85
PDF
Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies
2008
·
José Cangiano
, Barbara A. Centeno
, et al.
·
Digestive Diseases and Sciences
·
6
A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin’s lymphoma (NHL): Gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim
2006
·
F. Cabanillas
, I. Liboy
, et al.
·
Journal of Clinical Oncology
·
6
GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin’s lymphoma (NHL)
2008
·
F. Cabanillas
, I. Liboy
, et al.
·
Journal of Clinical Oncology
·
3
Abstract P3-14-17: Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer
2013
·
N Rivera-Rodriguez
, F Cabanillas
, et al.
·
Cancer Research
·
2
The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)
2008
·
Fernando Cabanillas
, Jorge Toro
, et al.
·
Blood
·
2
High Incidence of Non-Neutropenic Infections Induced by Rituximab Plus Chemotherapy and Associated with Hypogammaglobulinemia: A Frequently Unrecognized and Easily Treatable Complication.
2005
·
Fernando Cabanillas
, Orestes Pavia
, et al.
·
Blood
·
2
Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer (crc)
2005
·
O. A. Pavia
, J. Cangiano
, et al.
·
Journal of Clinical Oncology
·
2
Clinically Discordant Indolent Lymphomas: A Subset of Indolent NHLs with a Less Favorable Prognosis and Propensity to Transform
2015
·
Fernando Cabanillas
, Noridza Rivera
, et al.
·
Blood
·
1
Results of a novel neoadjuvant chemotherapy (NAC) regimen for breast cancer.
2013
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
·
1
Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfi lgrastim as support
2012
·
Fernando Cabanillas
, Maribel Cotto
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
1
Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease.
2011
·
M. Cotto
, F. Cabanillas
, et al.
·
Journal of Clinical Oncology
·
1
Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC).
2010
·
M. Cotto
, J. Toro
, et al.
·
Journal of Clinical Oncology
·
1
Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL).
2006
·
Fernando Cabanillas
, Jorge Toro
, et al.
·
Blood
·
1
Results of upfront therapy for marginal zone lymphoma (MZL).
2013
·
Fernando Cabanillas
, Jose Luis Ortega
, et al.
·
Journal of Clinical Oncology
The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)
2012
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Blood
Predicting Oncotype DX score with clinicopathological variables.
2012
·
Valmarie Ramos-Lamboy
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
Phase II study of a novel neoadjuvant chemotherapy (NAC) for breast cancer (BC).
2012
·
Miguel E. Albino
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
Absolute lymphocyte count (ALC), absolute monocyte count (AMC), and ALC/AMC ratio to predict outcome in aggressive non-Hodgkin lymphoma (aNHL).
2012
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).
2010
·
Maribel Cotto
, Fernando Cabanillas
, et al.
·
Blood
Dose-seeking study of the combination of GM-CSF with pegfilgrastim plus CHOP-rituximab in patients with aggressive non- Hodgkin lymphoma (NHL)
2007
·
F. Cabanillas
, O. Pavia
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
21
Citation count:
114
H-index:
3
I10-index:
1
Year
Topic
Type